7TM Pharma Enters Discovery Collaboration with Ortho-McNeil To Develop Novel Compounds for Asthma and Allergic Diseases
7TM Pharma A/S announced that it has entered into an exclusive worldwide license agreement and research collaboration with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, to further develop 7TM Pharma's program on novel oral compounds for the treatment of asthma and allergic diseases.
Under the agreement, 7TM Pharma will receive an upfront fee, research funding and milestones, as well as royalties on sales for each compound developed under the collaboration. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), also a Johnson & Johnson company, will be responsible for the development of compounds resulting from the collaboration.
The basis for the collaboration is 7TM Pharma's drug discovery platform, Site-Directed Drug Discovery®, and one of its resulting drug discovery programs targeting the discovery of novel antagonists to a certain 7-transmembrane receptor.
"The productivity and speed with which we have been able to move our asthma and allergic diseases program reflects 7TM Pharma's drug discovery capabilities as well as the value of our structure-based, proprietary SiteDirected Drug Discovery® platform approach," said Mette Kirstine Agger, CEO of 7TM Pharma. "We look forward to collaborating with Ortho-McNeil and J&JPRD as we search for new drug candidates in this therapeutic area."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
